Cardiovascular

FDA approves Belviq for treatment of obesity

On June 27, the U.S. Food and Drug Administration approved Belviq (lorcaserin hydrochloride) for the treatment of obesity. It is to be used in combination with a reduced-calorie diet and exercise for chronic weight management. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares